Related Experiment Video
Updated: Mar 27, 2026
Profiling Anti-Neu5Gc IgG in Human Sera with a Sialoglycan Microarray Assay
Published on: July 13, 2017
Evaluation of serum granulysin as a potential biomarker for nasopharyngeal carcinoma
Jianhua Lin1, Yingying Huang2, Lin Zhang1
1Department of Clinical Laboratory, State Key Laboratory of Oncology in South China, Cancer Center of Sun Yat-sen University, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, PR China.
Background:
Granulysin (GNLY) is excreted from cytotoxic T lymphocytes and natural killer cells, and plays an important role in antitumor immunity. However, few studies have estimated serum GNLY concentrations in patients with nasopharyngeal carcinoma (NPC). We evaluated GNLY as a potential biomarker for NPC.
Methods:
Serum GNLY concentrations were measured in blood samples taken from 98 NPC patients, 56 nasopharyngitis (NPT) patients, and 99 healthy subjects. The clinical relevance of GNLY in NPC was also investigated. We also assessed the association between serum GNLY and serum immunoglobulin A antibodies against the Epstein-Barr virus (EBV) viral capsid antigen (VCA-IgA) and EBV DNA.
Results:
Serum GNLY levels were significantly lower in NPC patients and significantly higher in nasopharyngitis patients compared to healthy controls. Thus, serum GNLY performs well as a biomarker for distinguishing between NPC and NPT. The serum GNLY concentration is elevated with corresponding increases in clinical stage and shows a significant correlation with VCA-IgA and EBV DNA concentration.
Conclusions:
Serum GNLY is closely associated with the clinical characteristics of NPC and may be a potential biomarker for NPC.
